Skip to main content
PMC home page
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 1991 Sep;50(9):631–633. doi: 10.1136/ard.50.9.631

Effects of pyrazinamide, probenecid, and benzbromarone on renal excretion of oxypurinol.

T Yamamoto 1, Y Moriwaki 1, S Takahashi 1, M Suda 1, K Higashino 1
PMCID: PMC1004507  PMID: 1929586

Abstract

The effects of pyrazinamide, probenecid, and benzbromarone on renal excretion of oxypurinol were investigated. Pyrazinamide decreased the mean (SEM) fractional clearance of oxypurinol from 19.2 (2.1) to 8.8 (1.5). Probenecid increased the fractional clearance of oxypurinol from 14.1 (3.5) to 24.8 (4.1). Benzbromarone increased the fractional clearance of oxypurinol from 15.6 (2.3) to 33.8 (2.8). These results suggest that oxypurinol may be secreted by 'an organic acid system' and that oxypurinol is reabsorbed at a putative postsecretory site of the renal tubules.

Full text

PDF
631

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Appelbaum S. J., Mayersohn M., Dorr R. T., Perrier D. Allopurinol kinetics and bioavailability. Intravenous, oral and rectal administration. Cancer Chemother Pharmacol. 1982;8(1):93–98. doi: 10.1007/BF00292878. [DOI] [PubMed] [Google Scholar]
  2. Berlinger W. G., Park G. D., Spector R. The effect of dietary protein on the clearance of allopurinol and oxypurinol. N Engl J Med. 1985 Sep 26;313(13):771–776. doi: 10.1056/NEJM198509263131302. [DOI] [PubMed] [Google Scholar]
  3. Breithaupt B., Tittel M. Kinetics of allopurinol after single intravenous and oral doses. Noninteraction with benzbromarone and hydrochlorothiazide. Eur J Clin Pharmacol. 1982;22(1):77–84. doi: 10.1007/BF00606429. [DOI] [PubMed] [Google Scholar]
  4. Colin J. N., Farinotti R., Fredj G., Tod M., Clavel J. P., Vignon E., Dietlin F. Kinetics of allopurinol and oxipurinol after chronic oral administration. Interaction with benzbromarone. Eur J Clin Pharmacol. 1986;31(1):53–58. doi: 10.1007/BF00870986. [DOI] [PubMed] [Google Scholar]
  5. Elion G. B., Yü T. F., Gutman A. B., Hitchings G. H. Renal clearance of oxipurinol, the chief metabolite of allopurinol. Am J Med. 1968 Jul;45(1):69–77. doi: 10.1016/0002-9343(68)90008-9. [DOI] [PubMed] [Google Scholar]
  6. Garcia Puig J., Mateos Antón F., Muñoz Sanz A., Gaspar G., Lesmes A., Ramos T., Ortiz Vázquez J. Renal handling of uric acid in normal subjects by means of the pyrazinamide and probenecid tests. Nephron. 1983;35(3):183–186. doi: 10.1159/000183071. [DOI] [PubMed] [Google Scholar]
  7. Hande K., Reed E., Chabner B. Allopurinol kinetics. Clin Pharmacol Ther. 1978 May;23(5):598–605. doi: 10.1002/cpt1978235598. [DOI] [PubMed] [Google Scholar]
  8. Löffler W., Gröbner W., Zöllner N. Harnsäuresenkende Wirkung einer Kombination von Benzbromaron und Allopurinol - Untersuchungen unter standardisierten Ernährungsbedingungen. Arzneimittelforschung. 1983;33(12):1687–1691. [PubMed] [Google Scholar]
  9. Mertz D. P., Eichhorn R. Does benzbromarone in therapeutic doses raise renal excretion of oxipurinol? Klin Wochenschr. 1984 Dec 17;62(24):1170–1172. doi: 10.1007/BF01712184. [DOI] [PubMed] [Google Scholar]
  10. Reiter S., Simmonds H. A., Webster D. R., Watson A. R. On the metabolism of allopurinol. Formation of allopurinol-1-riboside in purine nucleoside phosphorylase deficiency. Biochem Pharmacol. 1983 Jul 15;32(14):2167–2174. doi: 10.1016/0006-2952(83)90222-8. [DOI] [PubMed] [Google Scholar]
  11. Steele T. H., Boner G. Origins of the uricosuric response. J Clin Invest. 1973 Jun;52(6):1368–1375. doi: 10.1172/JCI107309. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Tofuku Y., Kuroda M., Takeda R. Hypouricemia due to renal urate wasting. Two types of tubular transport defect. Nephron. 1982;30(1):39–44. doi: 10.1159/000182430. [DOI] [PubMed] [Google Scholar]
  13. Yamamoto T., Moriwaki Y., Takahashi S., Hada T., Higashino K. Rapid and simultaneous determination of pyrazinamide and its major metabolites in human plasma by high-performance liquid chromatography. J Chromatogr. 1987 Jan 23;413:342–346. doi: 10.1016/0378-4347(87)80251-7. [DOI] [PubMed] [Google Scholar]
  14. Yamamoto T., Moriwaki Y., Takahashi S., Hada T., Higashino K. Separation of hypoxanthine and xanthine from pyrazinamide and its metabolites in plasma and urine by high-performance liquid chromatography. J Chromatogr. 1986 Oct 31;382:270–274. doi: 10.1016/s0378-4347(00)83528-8. [DOI] [PubMed] [Google Scholar]
  15. de Vries A., Sperling O. Inborn hypouricemia due to isolated renal tubular defect. Biomedicine. 1979 Jun;30(2):75–80. [PubMed] [Google Scholar]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES